

Index

- ACE2 receptors, 53–55, 85
Acute respiratory distress syndrome (ARDS), 104
Adaptive immune response, 108
Adenovirus vector vaccines, 100–101
Age
 children, prevalence of COVID-19 in, 65–66
 common misconceptions regarding, 119
 effect on severity of COVID-19, 15–16, 64–65
 hospitalization by, 61
 influenza, effect on severity of, 16, 97
 SARS, effect on severity of, 59–60, 85
 Spanish Influenza, effect on severity of, 91
AIDS (Acquired immunodeficiency syndrome) as viral disease, 24
Alphacoronavirus, 25–26
Alpha variant, 70–76
Anaphylaxis, 112
Antibodies
 different types of immune responses, 67–68
 in mild cases, 103
 monoclonal antibodies, 105
 predisposition and, 63–64
 testing, 102–104
Asian Influenza (1959), 93, 95, 116–117
Asymptomatic cases
 prevalence of, 59–60
 of SARS, 84
 severe cases, comparison with, 62–63
 unanswered questions regarding, 115
Attack rate, 9–10, 13
Basic reproduction number (R_0)
 in COVID-19, 10–12
 exponential growth in number of infections and, 12
 in influenza, 11–12
 low R_0 , 10
 in measles, 12
 in MERS, 11
 in Spanish Influenza, 11–12
 super spreaders and, 83
Bats
 COVID-19, as suspected origin of, 49–53, 78–79
 MERS, as suspected origin of, 82
 SARS, as suspected origin of, 51–53, 78–79, 81–82
Betacoronavirus
 bats, suspected origin in, 51–53
 classification of, 26
 emergence of, 47
 MERS-CoV as, 26

- overview, 26
- phylogenetic trees and, 52–54
- recombination of, 39–40
- SARS-CoV as, 26
- SARS-CoV-2 as, 26, 46–48
- Beta variant, 70–76
- Blood clots, 57, 112
- B.1.1.7 variant, 70–76
- B.1.351 variant, 70–76
- B.1.427 variant, 73–74
- B.1.429 variant, 73–74
- B.1.526 variant, 74
- B.1.617 variant, 72
- Breakthrough cases, 110–112
- Brenner, Sydney, 34, 100

- Camels as suspected origin of MERS, 82
- Canada, SARS in, 79
- Canine coronavirus, 26
- Cardiovascular disease, effect on severity of COVID-19, 64
- Case fatality rate
 - in COVID-19, 12, 57–59
 - infection fatality rate versus, 12, 57–59
 - in SARS, 84
 - in Spanish Influenza, 95
- Centers for Disease Control and Prevention, 95
- Children
 - common misconceptions regarding, 119
 - prevalence of COVID-19 in, 65–66
 - SARS, prevalence of, 65–66
 - unanswered questions regarding, 115
- China
 - age, effect on severity of COVID-19 in, 16
 - Chinese Center for Disease Control and Prevention (CCDC), 1, 16
 - clinical characteristics of COVID-19 in, 57–58
 - excess mortality in, 16
 - outbreak of COVID-19 in, 1, 46, 48, 50
 - SARS, outbreak of, 79
- Clinical characteristics of COVID-19, 56–58
- Co-infections, 104
- Common cold
 - as alphacoronavirus, 25–26
 - incubation period, 9
- Common misconceptions regarding
 - COVID-19
 - age and, 119
 - children and, 119
 - containment measures and, 119
 - extraterrestrial origin theory of viruses and, 119–120
 - influenza versus, 118
 - mortality rate and, 118
 - overview, 2
 - SARS versus, 118–119
 - Spanish Influenza versus, 118
- Contact tracing, 119
- Containment measures
 - common misconceptions regarding, 119
 - contact tracing, 119
 - public gatherings, banning of, 17, 94–95, 98
 - quarantine, 9, 11, 17, 80, 98
 - social distancing, 11, 17–19, 98, 119
 - in Spanish Influenza, 94–95, 98, 119
- CoronaVac vaccine, 100–101, 110
- Coronaviruses. *See also specific coronavirus*
 - alphacoronavirus, 25–26
 - betacoronavirus (See Betacoronavirus)
 - canine coronavirus, 26
 - definition of coronavirus, 24
 - deltacoronavirus, 26
 - DNA in, 24–25
 - entry into cells, 30
 - feline coronavirus, 26
 - gammacoronavirus, 26

138 INDEX

- Coronaviruses (cont.)
 hosts, 26
 identification of, 24
 mutation of (See Mutation of coronaviruses)
 non-structural proteins in, 27–28
 origins of, 49
 overview, 3–4, 23
 previous infections protecting against COVID-19, unanswered questions regarding, 116
 proofreading system, 36
 recombination of (See Recombination of coronaviruses)
 release from cells, 32–33
 replication of, 30
 RNA in, 24–25, 27–30
 Spike proteins in, 27, 30, 53
 structural proteins in, 27
 structure of, 24–25, 27–30
 suggested further reading, 122–123
 viral genome of, 29–30
 COVID-19. *See specific topic*
- Deltacoronavirus, 26
- Diabetes, effect on severity of COVID-19, 64
- Diagnosis of COVID-19, 100–101
 Polymerase Chain Reaction (PCR) testing, 101–102
 serology testing, 102–104
- Difficulty in controlling COVID-19, 86
- Digestive system, effects of COVID-19 on, 57
- Diversification. *See Mutation of coronaviruses*
- DNA
 in coronaviruses, 24–25
 mutation of coronaviruses and, 36–37
 Polymerase Chain Reaction (PCR) testing and, 101–102
 in viruses, 24
- Dobzhansky, Theodosius, 34
- Dogs as suspected origin of SARS, 81
- Drugs
 for Ebola virus, 105
 favilavir, 105
 for HIV, 106
 hydroxychloroquine, 106
 for influenza, 97
 lopinavir, 106
 monoclonal antibodies, 105
 overview, 105
 remdesivir, 105
 ritonavir, 106
 for SARS, 105
- Dysregulation of immune response, 105–106
- Ebola virus
 drugs for, 105
 emergence of, 117
 infection fatality rate, 13
- Economic effects of COVID-19, 2
- E484K mutation, 73–74
- Epidemiology of COVID-19
 age, effect on severity, 15–16
 attack rate, 9–10, 13
 basic reproduction number (R_0), 10–12
 case fatality rate, 12
 definition of epidemiology, 7
 excess mortality, 15, 60–61
 exponential growth, 10–11
 “flattening the curve,” 18
 gender, effect on severity, 16–17
 herd immunity, 19–21
 incubation period, 8–9
 infection fatality rate, 12–13
 mortality rate, 12–13
 number of confirmed COVID-19 cases, 8
 overview, 3, 7–8
 suggested further reading, 121–122
 unanswered questions regarding, 114

- Evolution, 34
- Excess mortality, 15, 60–61
- Exponential growth, 10–11
- Extraterrestrial origin theory of viruses, 119–120
- Face masks, 70
- Family clusters, SARS in, 79
- Fauci, Anthony, 45
- Favilavir, 105
- Feline coronavirus, 26
- “Flattening the curve,” 17–19
- Foshan (China), outbreak of SARS in, 79
- Galen, 100
- Gammacoronavirus, 26
- Gender
 - effect on severity of COVID-19, 16–17, 45–65
 - influenza, effect on severity, 16–17
 - SARS, effect on severity of, 59–60, 85
- Genetic determinants of COVID-19, 61–63
- Genetic markers and COVID-19, unanswered questions regarding, 115
- Genomes. *See* Viral genomes
- Globalization and COVID-19, 117
- Global pandemics
 - Asian Influenza (1959), 93, 95, 116–117
 - COVID-19, declaration of, 1–2, 48
 - Hong Kong Influenza (1968), 93, 95, 116–117
 - pandemic influenza, 91–95
 - Spanish Influenza (*See* Spanish Influenza (1918))
 - 2009 influenza pandemic, 93, 95, 116–117
- Guangdong Province (China), outbreak of SARS in, 79, 81
- Guangzhou (China), SARS in, 81
- Health care workers, SARS in, 79
- Health Organization (League of Nations), 99
- Heart, effects of COVID-19 on, 57
- Hepatitis B, 108
- Herd immunity, 20
 - definition of herd immunity, 19–21
 - likelihood of development, 116–117
 - measles and, 19
 - unanswered questions regarding, 115
- History of COVID-19. *See* Epidemiology of COVID-19
- HIV (Human Immunodeficiency Virus)
 - AIDS as viral disease, 24
 - drugs for, 106
 - emergence of, 117
 - mutation of viruses and, 38
 - overview, 3
- H1N1 influenza
 - emergence of, 117
 - pandemic associated with (*See* Spanish Influenza (1918))
 - structure of, 89
- Hong Kong, SARS in, 79, 83
- Hong Kong Influenza (1968), 93, 95, 116–117
- Hospitalization by age, 61
- Huanan Seafood Wholesale Market (Wuhan), 1, 46, 50–51
- Hubei Province (China), outbreak of COVID-19 in, 1, 46
- Hydroxychloroquine, 106
- Hypertension, effect on severity of COVID-19, 64
- Iceland, mortality rate in, 59
- Identification of COVID-19, 1
- Immune memory, 67–68
- Immune recognition, 23
- Immune system and COVID-19
 - adaptive immune response, 108

140 INDEX

- Immune system and COVID-19 (cont.)
 different types of immune responses,
 67–68
 dysregulation of immune response,
 105–106
 immune memory, 67–68
 immune recognition, 23
 innate immune response, 106–107
 modulation of immune response,
 105–106
 predisposition and, 63–64
 recognition of virus, 108–109
 unanswered questions regarding, 114
- Immunity
 herd immunity (See Herd immunity)
 unanswered questions regarding,
 115
- Inactivated virus vaccines, 100–101, 110
- Inborn errors, predisposition to
 COVID-19 and, 63–64
- Incubation period
 in common cold, 9
 in COVID-19, 8–9
 in influenza, 9, 97
 in rabies, 9
 in SARS, 9, 84
- Infection fatality rate
 case fatality rate versus, 12, 57–59
 in COVID-19, 12–13, 57–59
 of Ebola virus, 13
 mortality rate distinguished, 12–13
 in Spanish Influenza, 13, 95
- Influenza
 age, effect on severity, 16, 97
 Asian Influenza (1959), 93, 95,
 116–117
 basic reproduction number (R_0), 11–12
 common misconceptions regarding,
 118
 COVID-19 compared, 5–6, 88, 97–98
 drugs for, 97
 entry into cells, 88–89
 favilavir for, 105
 “flattening the curve” and, 17
 gender, effect on severity, 16–17
 herd immunity and, 19
 Hong Kong Influenza (1968), 93, 95,
 116–117
 hosts, 90
 incubation period, 9, 97
 mutation of viruses and, 38, 90, 95
 1959 pandemic, 93, 95, 116–117
 1968 pandemic, 93, 95, 116–117
 overview, 5–6, 86–87
 pandemic influenza, 91–95
 phylogenetic trees and, 43–44
 reassortment of viruses, 89–92
 replication time, 88–89, 97
 respiratory problems in, 97
 seasonal influenza, 95–96
 Spanish Influenza (See Spanish
 Influenza (1918))
 statistics, 95
 suggested further reading, 128–129
 symptoms of, 97
 transmission of, 96–98
 2009 pandemic, 93, 95, 116–117
 vaccines for, 97–98, 109
 as viral disease, 24
- Innate immune response, 106–107
- International Committee on Taxonomy of
 Viruses (ICTV), 46, 85
- Iran, outbreak of COVID-19 in, 48
- Italy
 excess mortality in, 16
 mutation of SARS-CoV-2 in, 71–72
 outbreak of COVID-19 in, 48
- Jacob, Francois, 34
- Japan
 median age in, 16
 outbreak of COVID-19 in, 48
- Johnson & Johnson vaccine, 100–101,
 110, 112

- Kidneys, effects of COVID-19 on, 57
Kierkegaard, Søren, 114
- League of Nations, 99
Lederberg, Joshua, 1
Levine, Arnold, 1
Live attenuated virus vaccines, 110
“Long COVID,” 68–69
“Long-haulers,” 68–69, 116
Long-term effects of COVID-19, 68–69, 116
Lopinavir, 106
- Magee, Steven, 88
Management of COVID-19, 104
Masks, 70
Measles
 basic reproduction number (R_0), 12
 herd immunity and, 19
 vaccines for, 108
 as viral disease, 24
Mechanisms of COVID-19, unanswered questions regarding, 114
Medawar, Peter, 22
Mental health effects of COVID-19, 69
MERS
 basic reproduction number (R_0), 11
 bats as suspected origin of, 82
 camels as suspected origin of, 82
 hosts, 26
 naming of, 45
 in South Korea, 83
 super spreaders, 83
MERS-CoV
 basic reproduction number (R_0), 11
 bats as suspected origin of, 82
 as betacoronavirus, 26
 camels as suspected origin of, 82
 emergence of, 47, 117
 hosts, 26
 naming of, 45
Middle East respiratory syndrome. *See* MERS
 coronavirus. *See* MERS-CoV
Migration and COVID-19, 117
Mild cases
 of SARS, 84
 unanswered questions regarding, 115
Modelling, 115
Moderna vaccine, 100–101, 109–110
Modulation of immune response, 105–106
Monoclonal antibodies, 105
Mortality rate
 common misconceptions regarding, 118
 of COVID-19, 59
 excess mortality, estimating, 15, 60–61
 illustration of, 13
 infection fatality rate distinguished, 12–13
 of smallpox, 3
 of Spanish Influenza, 91, 93
 World Health Organization on, 59
Mukherjee, Siddhartha, 78
Mumps, 108
Mutation of coronaviruses
 accumulation of, 72
 definition of mutation, 35
 diversity of species, across, 37–38
 DNA and, 36–37
 E484K mutation, 73–74
 evolution and, 34
 influenza and, 38, 90, 95
 overview, 4–5, 34–35
 phylogenetic trees and, 42–43
 recombination (*See* Recombination of coronaviruses)
 replication time, 36–38
 RNA and, 35–38
 SARS-CoV-2, 36, 66, 71–72
 “slowness,” 4–5, 35, 41
 suggested further reading, 123
 tracking origins of outbreaks using, 41–43

142 INDEX

- Mutation of coronaviruses (cont.)
 unanswered questions regarding, 116
 variants generated from, 72
 viral genomes and, 36–37
- Naming of viruses and diseases
 COVID-19, 45–46, 85–86
 MERS, 45
 MERS-CoV, 45
 SARS, 45–46, 85–86
 SARS-CoV, 45–46
 SARS-CoV-2, 45–46
 Spanish Influenza, 91
- New York City, Spanish Influenza in, 95
- Novavax vaccine, 110
- Novel RNA vaccines, 100–101
- Nucleic acid vaccines, 109–110
- Number of persons infected
 unanswered questions regarding, 115
 World Health Organization on, 8
- Other medical factors, effect on severity of
 COVID-19, 64
- Oxford–AstraZenaca vaccine, 100–101,
 110, 112
- Oxygen therapy, 104
- Palm civets as suspected origin of SARS,
 81
- Pandemic influenza, 91–95
- PCR (Polymerase Chain Reaction) testing,
 101–102
- Pfizer–BioNTech vaccine, 100–101,
 109–111
- Philadelphia (Pennsylvania), Spanish
 Influenza in, 98
- Phylogenetic Assignment of Named
 Global Outbreak (PANGO), 70–75
- Phylogenetic trees, 42–43, 52–54
- Polio, 12
- Polymerase Chain Reaction (PCR) testing,
 101–102
- P.1 variant, 73–74
- Population growth and COVID-19, 117
- Proofreading system, 36
- Protein subunit vaccines, 110
- Public gatherings, banning of, 17, 94–95,
 98
- Public health systems, 98–99
- Pybus, Oliver, 74
- Quarantine, 9, 11, 17, 80, 98
- Rabies
 incubation period, 9
 as viral disease, 24
- Rambaut, Andrew, 74
- Receptor binding domain (RBD), 55–56
- Recombination of coronaviruses
 betacoronavirus, 39–40
 definition of recombination, 38
 exchange of genomic material, 39
 overview, 4–5, 35
 RNA and, 38
 SARS-CoV, 53–54
 SARS-CoV-2, 40, 53–54
 “sloppiness” compared, 41
- Remdesivir, 105
- Respiratory problems
 acute respiratory distress syndrome
 (ARDS), 104
 in COVID-19, 56–58
 effect on severity of COVID-19, 64
 in influenza, 97
 in SARS, 84
- Ritonavir, 106
- RNA
 in coronaviruses, 24–25, 27–30
 mutation of coronaviruses and, 35–38
 recombination of coronaviruses and,
 38
 in viruses, 24
- Rotavirus, 3
- Rubella, 108

- St. Louis (Missouri), Spanish Influenza in, 98
- SARS (2002-2003). *See also* SARS-CoV
 age, effect on severity, 59–60, 85
 asymptomatic cases, 84
 bats as suspected origin of, 51–53, 78–79, 81–82
 case fatality rate in, 84
 children, prevalence in, 65–66
 clinical characteristics of, 84–85
 common misconceptions regarding, 118–119
 control of, 86
 COVID-19 compared, 5, 78–79
 dogs as suspected origin of, 81
 drugs for, 105
 family clusters, 79
 gender, effect on severity, 59–60, 85
 in health care workers, 79
 hosts, 26
 incubation period, 9, 84
 long-term effects of, 86
 mild cases, 84
 naming of, 45–46, 85–86
 overview, 5, 77–79
 palm civets as suspected origin of, 81
 pathology of, 84–85
 respiratory problems in, 84
 species contracting, 24–25
 suggested further reading, 126
 super spreaders, 83
 symptoms of, 84
 unreported cases, 84
 World Health Organization and, 79, 86
- SARS-CoV. *See also* SARS (2002-2003)
 ACE2 receptors and, 53–55, 85
 bats as suspected origin of, 51–53, 78–79, 81–82
 as betacoronavirus, 26
 dogs as suspected origin of, 81
 emergence of, 47
 entry into cells, 30, 53–55
 genetic similarities and differences to SARS-CoV-2, 85
 identification of, 80
 naming of, 45–46
 overview, 5
 palm civets as suspected origin of, 81
 phylogenetic trees and, 52–54
 receptor binding domain (RBD) and, 55–56
 recombination of, 53–54
 relation to SARS-CoV-2, 52–54
 SARS-CoV-2 compared, 5, 78–80, 85
 viral genome of, 30–31, 80
 viral shedding of, 86
- SARS-CoV-2
 ACE2 receptors and, 53–55
 bats, suspected origin in, 49–53, 78–79
 as betacoronavirus, 26, 46–48
 entry into cells, 30, 53–55
 genetic similarities and differences to SARS-CoV, 85
 hosts, 26
 mutation of, 36, 66, 71–72
 naming of, 45–46
 overview, 3–5, 45
 phylogenetic trees and, 52–54
 receptor binding domain (RBD) and, 55–56
 recombination of, 40, 53–54
 relation to SARS-CoV, 52–54
 release from cells, 33
 SARS-CoV compared, 5, 78–80, 85
 Spike proteins in, 53
 spreading of, 55–56
 suggested further reading, 123–126, 130
 super spreaders, 55–56
 variants, 72–77 (*See also* Variants of SARS-CoV-2)
 viral genome of, 5, 29–30
 viral shedding of, 56, 86
 where first reported, 46–48

144 INDEX

- Seasonal influenza, 95–96
- Sepsis, 104
- Serology testing, 102–104
- Severe acute respiratory syndrome
coronavirus (SARS-CoV). *See* SARS-CoV
- Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). *See* SARS-CoV-2
- Severe acute respiratory syndrome (SARS)
(2002-2003). *See* SARS (2002-2003)
- Shenzhen (China), SARS in, 81
- Shope, Robert, 7
- Singapore, SARS in, 79, 83–84
- Sinopharm vaccine, 100–101, 110
- Skin conditions, 57
- “Sloppiness” in coronaviruses, 4–5, 35, 41
- Smallpox
mortality rate, 3
vaccines for, 108–109
as viral disease, 24
- Smell, loss of, 67–68
- Social distancing, 11, 17–19, 98, 119
- South Korea
“flattening the curve” in, 17–19
MERS in, 83
- Spain
excess mortality in, 15–16
outbreak of COVID-19 in, 48
- Spanish Influenza (1918)
age, effect on severity, 91
attack rate, 9–10
basic reproduction number (R_0), 11–12
case fatality rate, 95
common misconceptions regarding, 118
containment measures in, 94–95, 98, 119
COVID-19 compared, 6, 88
infection fatality rate, 13, 95
mortality rate, 91, 93
naming of, 91
narrative description of, 91–94
overview, 3, 86–87, 116–117
overwhelming of health care system by, 94
public health systems and, 98–99
suggested further reading, 128–129
waves of, 95, 116
- Spike proteins, 27, 30, 53
- Spread of COVID-19. *See* Epidemiology of COVID-19
- Sputnik V vaccine, 100–101, 110
- Super spreaders
basic reproduction number (R_0) and, 83
contributing factors, 83–84
of COVID-19, 55–56
defined, 70–71
of MERS, 83
prevalence of, 70–71
of SARS, 83
- Surge capacity, 18
- Symptoms of COVID-19, 56–58
- Taiwan, SARS in, 79
- Taste, loss of, 67–68
- Testing
antibody testing, 102–104
“flattening the curve” and, 17–19
Polymerase Chain Reaction (PCR) testing, 101–102
serology testing, 102–104
suggested further reading, 129–130
- Thailand, outbreak of COVID-19 in, 48
- Therapies
for acute respiratory distress syndrome (ARDS), 104
co-infections and, 104
drugs (*See* Drugs)
increased knowledge and technology, role of, 116
management, 104

- oxygen therapy, 104
- for sepsis, 104
- suggested further reading, 129–130
- testing (See Testing)
- treatment, 104
- vaccines (See Vaccines)
- Thomas, Lewis, 22
- Time lag in fatal cases of COVID-19, 59
- Treatment of COVID-19, 104

- United Nations, 99
- United States
 - mutation of SARS-CoV-2 in, 66, 71–72
 - Spanish Influenza in, 17
- Unreported cases
 - case fatality rate versus infection
 - fatality rate, 12, 57–59
 - of SARS, 84
 - unanswered questions regarding, 115
- USS *Theodore Roosevelt*, 70

- Vaccines
 - adenovirus vector vaccines,
 - 100–101
 - breakthrough cases, 110–112
 - CoronaVac vaccine, 100–101, 110
 - duration of protection, 112–113
 - efficacy of, 109, 111
 - inactivated virus vaccines, 100–101,
 - 110
 - increased knowledge and technology,
 - role of, 116
 - for influenza, 97–98
 - Johnson & Johnson vaccine, 100–101,
 - 110, 112
 - live attenuated virus vaccines, 110
 - for measles, 108
 - mechanisms of, 108–109
 - Moderna vaccine, 100–101, 109–110
 - Novavax vaccine, 110
 - novel RNA vaccines, 100–101
 - nucleic acid vaccines, 109–110
 - Oxford–AstraZenaca vaccine,
 - 100–101, 110, 112
 - Pfizer–BioNTech vaccine, 100–101,
 - 109–111
 - protein subunit vaccines, 110
 - secondary effects of, 112
 - side effects of, 112
 - Sinopharm vaccine, 100–101, 110
 - for smallpox, 108–109
 - Sputnik V vaccine, 100–101, 110
 - successful development of, 100–101
 - types of vaccines, 109–111
 - viral vector vaccines, 110
- Variants of SARS-CoV-2, 72–77
 - Alpha variant, 70–76
 - Beta variant, 70–76
 - B.1.1.7 variant, 70–76
 - B.1.351 variant, 70–76
 - B.1.427 variant, 73–74
 - B.1.429 variant, 73–74
 - B.1.526 variant, 74
 - B.1.617 variant, 72
 - E484K mutation, 73–74
 - mutations, generated from, 72
 - naming of, 70–75
 - P.1 variant, 73–74
 - variants of concern, 73–74, 76–77
 - variants of interest, 74
- Vietnam, SARS in, 79
- Viral genomes
 - of coronaviruses, 29–30
 - genetic information encoded in, 24
 - mutation of coronaviruses and, 36–37
 - reading of, 4
 - of SARS-CoV, 30–31, 80
 - of SARS-CoV-2, 5, 29–30
- Viral shedding
 - of SARS-CoV, 86
 - of SARS-CoV-2, 56, 86
- Viral vector vaccines, 110
- Viruses. *See also specific virus*
 - coronaviruses (See Coronaviruses)

146 INDEX

- Viruses. (cont.)
 defined, 23
 diversity of, 24
 DNA in, 24
 identification of, 24
 immune recognition and, 23
 overview, 3–4, 22–23
 prevalence of, 24–25
 RNA in, 24
 size of, 23
 suggested further reading, 122–123
 viral genomes (*See* Viral genomes)
- Waves
 of Spanish Influenza, 95, 116
 unanswered questions regarding, 116
- West Nile virus, 105
- World Health Organization (WHO)
 daily reports by, 49
 global pandemic, declaration of, 1–2, 48
- on mortality rate of COVID-19, 59
 naming of COVID-19, 46, 85–86
 naming of variants and, 77
 number of confirmed COVID-19 cases, 8
 origins of, 99
 SARS and, 79, 86
 seasonal influenza and, 96
 vaccines and, 101, 109
- Wuhan (China)
 children, prevalence of COVID-19 in, 65–66
 lockdown of, 48
 mortality rate in, 59
 outbreak of COVID-19 in, 1, 46, 50
- Wuhan Institute of Virology, 50
- Yunnan Province (China), SARS in, 81
- Zhong, N.S., 78
 Zika virus, 117